1. Cancer cell-selective induction of mitochondrial stress and immunogenic cell death by PT-112 in human prostate cell lines.
- Author
-
Soler-Agesta, R., Moreno-Loshuertos, R., Yim, C. Y., Congenie, M. T., Ames, T. D., Johnson, H. L., Stossi, F., Mancini, M. G., Mancini, M. A., Ripollés-Yuba, C., Marco-Brualla, J., Junquera, C., Martínez-De-Mena, R., Enríquez, J. A., Price, M. R., Jimeno, J., and Anel, A.
- Subjects
ORGANELLE formation ,CASTRATION-resistant prostate cancer ,PROSTATE cancer ,CANCER cells ,CELL death ,CELL lines - Abstract
PT-112 is a novel immunogenic cell death (ICD)-inducing small molecule currently under Phase 2 clinical development, including in metastatic castration-resistant prostate cancer (mCRPC), an immunologically cold and heterogeneous disease state in need of novel therapeutic approaches. PT-112 has been shown to cause ribosome biogenesis inhibition and organelle stress followed by ICD in cancer cells, culminating in anticancer immunity. In addition, clinical evidence of PT-112-driven immune effects has been observed in patient immunoprofiling. Given the unmet need for immune-based therapies in prostate cancer, along with a Phase I study (NCT#02266745) showing PT-112 activity in mCRPC patients, we investigated PT-112 effects in a panel of human prostate cancer cell lines. PT-112 demonstrated cancer cell selectivity, inhibiting cell growth and leading to cell death in prostate cancer cells without affecting the non-tumorigenic epithelial prostate cell line RWPE-1 at the concentrations tested. PT-112 also caused caspase-3 activation, as well as stress features in mitochondria including ROS generation, compromised membrane integrity, altered respiration, and morphological changes. Moreover, PT-112 induced damage-associated molecular pattern (DAMP) release, the first demonstration of ICD in human cancer cell lines, in addition to autophagy initiation across the panel. Taken together, PT-112 caused selective stress, growth inhibition and death in human prostate cancer cell lines. Our data provide additional insight into mitochondrial stress and ICD in response to PT-112. PT-112 anticancer immunogenicity could have clinical applications and is currently under investigation in a Phase 2 mCRPC study. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF